Amgen, Inc. (NASDAQ:AMGN) Shares Sold by Rosenbaum Jay D.

Rosenbaum Jay D. decreased its position in Amgen, Inc. (NASDAQ:AMGN) by 2.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,416 shares of the medical research company’s stock after selling 210 shares during the quarter. Amgen accounts for about 3.3% of Rosenbaum Jay D.’s investment portfolio, making the stock its 6th largest holding. Rosenbaum Jay D.’s holdings in Amgen were worth $1,735,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Bangor Savings Bank lifted its stake in Amgen by 2.1% during the first quarter. Bangor Savings Bank now owns 2,682 shares of the medical research company’s stock worth $510,000 after purchasing an additional 55 shares during the last quarter. Carroll Financial Associates Inc. lifted its stake in Amgen by 0.8% during the second quarter. Carroll Financial Associates Inc. now owns 7,436 shares of the medical research company’s stock worth $1,370,000 after purchasing an additional 58 shares during the last quarter. Lincoln Capital Corp lifted its stake in Amgen by 0.3% during the second quarter. Lincoln Capital Corp now owns 21,483 shares of the medical research company’s stock worth $3,959,000 after purchasing an additional 58 shares during the last quarter. Slow Capital Inc. lifted its stake in Amgen by 0.4% during the second quarter. Slow Capital Inc. now owns 13,799 shares of the medical research company’s stock worth $2,543,000 after purchasing an additional 58 shares during the last quarter. Finally, CWM LLC lifted its stake in Amgen by 1.8% during the second quarter. CWM LLC now owns 3,271 shares of the medical research company’s stock worth $603,000 after purchasing an additional 59 shares during the last quarter. 78.96% of the stock is owned by institutional investors.

AMGN has been the topic of several research analyst reports. JPMorgan Chase & Co. restated a “hold” rating on shares of Amgen in a research note on Friday, August 9th. Cowen restated a “buy” rating and set a $229.00 price objective on shares of Amgen in a research note on Wednesday, May 1st. Oppenheimer raised their price objective on Amgen from $210.00 to $230.00 and gave the stock an “outperform” rating in a research note on Tuesday. Mizuho restated a “buy” rating and set a $208.00 price objective on shares of Amgen in a research note on Monday, July 1st. Finally, BidaskClub upgraded Amgen from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Nine investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $211.44.

In related news, Director R Sanders Williams sold 425 shares of Amgen stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $183.04, for a total transaction of $77,792.00. Following the transaction, the director now directly owns 16,336 shares of the company’s stock, valued at $2,990,141.44. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $175.68, for a total value of $351,360.00. Following the transaction, the director now directly owns 16,219 shares in the company, valued at $2,849,353.92. The disclosure for this sale can be found here. Insiders have sold 4,425 shares of company stock worth $804,312 over the last three months. Corporate insiders own 0.25% of the company’s stock.

Shares of AMGN traded up $1.77 during trading hours on Thursday, reaching $200.64. 94,715 shares of the company’s stock traded hands, compared to its average volume of 3,546,323. The company has a market cap of $119.83 billion, a price-to-earnings ratio of 13.94, a price-to-earnings-growth ratio of 2.42 and a beta of 1.19. The company has a debt-to-equity ratio of 2.58, a current ratio of 2.89 and a quick ratio of 2.60. Amgen, Inc. has a twelve month low of $166.30 and a twelve month high of $211.90. The stock has a fifty day simple moving average of $183.21.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, July 30th. The medical research company reported $3.97 EPS for the quarter, beating analysts’ consensus estimates of $3.58 by $0.39. The company had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The company’s quarterly revenue was down 3.1% compared to the same quarter last year. During the same period last year, the company earned $3.83 earnings per share. On average, research analysts forecast that Amgen, Inc. will post 14.25 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 6th. Stockholders of record on Thursday, August 15th will be issued a dividend of $1.45 per share. This represents a $5.80 dividend on an annualized basis and a dividend yield of 2.89%. The ex-dividend date is Wednesday, August 14th. Amgen’s dividend payout ratio (DPR) is 40.28%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Read More: What factors cause inflation to rise?

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.